OSE 2101
OSE Immunotherapeutics
['ovarian', 'tedopi', 'sclc', 'nsclc', 'oseimmuno']
asco 2023: ose presents clinical abstracts on tedopi , its most advanced product in clinical development, featuring data from the positive phase 3 of tedopi in nsclc and from phase 2 of tedopi in combination in ovarian cancer.
read more: 
focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases.